Real programs. Real gate outcomes.
Client identities are anonymized at their request, but every metric below is from a closed engagement with portfolio gate approval or investor diligence confirmation.
- 3–6×
- Faster than internal bioinformatics
- 847+
- Targets evaluated per program
- 100%
- Portfolio gate dossier acceptance
- 2–4 wks
- Typical delivery timeline
Three programs across target discovery domains
Select a case study to read the full engagement timeline, evidence dossiers, portfolio gate outcomes, and lessons learned.
Multi-Omics Target Discovery for Rheumatoid Arthritis
Pharma discovery group needed a ranked, druggable target list with evidence dossiers before Q4 portfolio gate—replacing a stalled GWAS-only internal analysis.
- 3 wks
- Computational delivery
- 847
- Targets evaluated
Alzheimer's Disease Target Prioritization Beyond Amyloid
Neuroscience biotech needed a diversified AD target portfolio with tau-independent mechanisms for Series B diligence—within 6 weeks of investor roadshow.
- 4 wks
- Computational delivery
- 1,204
- Targets evaluated
NSCLC EGFR-TKI Resistance Pathway Mapping
Oncology unit needed resistance mechanism targets for osimertinib-progressed patients to design combination strategy before Phase 1b trial protocol lock.
- 3 wks
- Computational delivery
- 634
- Resistance-associated nodes
Your indication could be the next case study.
Tell us about your disease area. We will scope a 2 to 4 week target discovery pilot.